NasdaqGS:INSMBiotechs
Is It Time To Reassess Insmed (INSM) After The Recent Share Price Pullback
Wondering whether Insmed at US$133.26 is offering fair value or stretching expectations? This article walks through how the current price stacks up against several valuation yardsticks.
The stock has had a mixed run recently, with a 1.4% decline over the last 7 days, an 18.0% decline over 30 days, and a 24.8% decline year to date, set against an 84.3% return over the past year and a very large return over three years.
These moves sit against a backdrop of ongoing interest in the biotech...